RBC Lifts Price Target on Ascendis Pharma, Backs Growth Trajectory Through 2026
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.